Competitive tension builds around Amgen's Tepezza after a fresh patent ruling

Edited by ad hoc news Products & Consumer Desk. Reviewed before publication on 06/15/2026 at 10:27 PM ET. Details in the imprint.

Amgen's Tepezza is back in the spotlight after a new U.S. patent verdict involving the company drew attention to the legal environment around its antibody portfolio. The drug itself remains a niche but important therapy for thyroid eye disease, and the company still markets it as the first FDA-approved treatment for that condition, with a list price that puts it among high-cost specialty medicinesofficial Tepezza product page.

What Tepezza does, and why it still matters

Tepezza, or teprotumumab-trbw, is an intravenous medicine for thyroid eye disease, an uncommon autoimmune condition that can cause eye bulging, double vision and pain. Amgen says the drug is given in eight infusions over about 24 weeks, which makes it a specialist treatment rather than a routine prescription therapyofficial Tepezza product page.

The product matters inside Amgen's portfolio because it sits in a category where a small patient base can still generate meaningful revenue if reimbursement holds up. Reuters reported that Harbour BioMed won a U.S. patent infringement case against Amgen, a reminder that the company's biologics business can face courtroom pressure even when the product itself is clinically establishedReuters report.

Amgen describes Tepezza as its only medicine approved for thyroid eye disease, and that exclusivity has made the product strategically visible despite its narrow indication. In practical terms, the drug's value comes from being a focused specialty asset, not from mass-market volume, which is why pricing, access and patent protection all matter at the same time.

Shares of Amgen Inc. (US0311621009) traded on NASDAQ at $280.98 on 06/15/2026, according to market data from MarketWatch, keeping the stock tied to the broader discussion around the company's biologics franchise rather than this one product alone.

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.